PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Pharmaceutical

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Subscribe now